Skip to main content

Advertisement

SpringerLink
Log in

Polymyalgia Rheumatica and Giant Cell Arteritis in Older Patients

Diagnosis and Pharmacological Management

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Giant cell arteritis (GCA) is an inflammatory vasculopathy that involves large- and medium-sized arteries and can cause vision loss, stroke and aneurysms. GCA occurs in people aged >50 years and is more common in women. A higher incidence of the disease is observed in populations from Northern European countries.

Polymyalgia rheumatica (PMR) is a periarticular inflammatory process manifesting as pain and stiffness in the neck, shoulders and pelvic girdle. PMR shares the same pattern of age and sex distribution as GCA. The pathophysiology of PMR and GCA is not completely understood, but the two conditions may be related and often occur concurrently.

A delay in the diagnosis should be avoided because of the risk of vascular ischaemic complications due to GCA. The diagnosis should be considered in patients aged >50 years presenting with symptoms such as new headache, visual disturbances, jaw claudication or symptoms of PMR. GCA can also present as a systemic inflammatory syndrome with fever of unknown origin. Marked elevation of acute-phase reactants, recognizable in higher erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels, is often seen in both PMR and GCA. However, some patients can present with a normal ESR. Confirmation of the diagnosis of GCA by temporal artery biopsy is important because clinical findings and laboratory tests are not specific, and because a diagnosis of GCA commits patients to long-term treatment with corticosteroids. The role of imaging techniques for the diagnosis of GCA remains unclear, but these modalities can be helpful in assessing the extent of vascular involvement, especially when extra-cranial disease is present. In PMR, subdeltoid and subacromial bursitis can be identified by imaging techniques, especially ultrasound or MRI.

The clinical manifestations of GCA and PMR respond dramatically within 12–48 hours of starting corticosteroid treatment. The initial corticosteroid dosage commonly used in GCA is oral prednisone 40–60 mg/day, and for patients with PMR a dosage of 15–20 mg/day is often sufficient. A prolonged course of treatment is necessary, and corticosteroids are gradually tapered, guided by regular clinical evaluation and ESR (and/or CRP) measurement. Methotrexate is the best studied corticosteroid-sparing agent in GCA, and may be useful for patients with frequent disease relapses and/or corticosteroid-related toxicity. Retrospective studies favour aspirin (acetylsalicylic acid) as an effective adjuvant treatment for reducing the ischaemic complications of GCA.

The long-term course of corticosteroid therapy frequently exposes elderly patients with PMR/GCA to various adverse effects, which can be attenuated with appropriate prophylactic measures. Co-morbid diseases and polypharmacy can pose particular challenges in the geriatric population. In general, the life expectancy of patients with GCA does not appear to be shortened, whereas the morbidity associated with the disease and its treatment is well recognized.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Similar content being viewed by others

References

  1. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008 Jul 19; 372(9634): 234–45

    Article  PubMed  Google Scholar 

  2. Weyand C, Goronzy J. Giant cell arteritis, polymyalgia rheumatica, and Takayasu’s arteritis. In: Klippel J, Stone J, Crofford L, et al., editors. Primer on the rheumatic diseases. New York (NY): Springer, 2008: 398–409

    Chapter  Google Scholar 

  3. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 2009 Oct 15; 61(10): 1454–61

    Article  PubMed  Google Scholar 

  4. Salvarani C, Crowson CS, O’Fallon WM, et al. Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period. Arthritis Rheum 2004 Apr 15; 51(2): 264–8

    Article  PubMed  Google Scholar 

  5. Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. N Engl J Med 2003 Jul 10; 349(2): 160–9

    Article  PubMed  CAS  Google Scholar 

  6. Schafer VS, Kermani TA, Crowson CS, et al. Incidence of herpes zoster in patients with giant cell arteritis: a population-based cohort study. Rheumatology (Oxford) 2010 Nov; 49(11): 2104–8

    Article  Google Scholar 

  7. Boesen P, Sorensen SF. Giant cell arteritis, temporal arteritis, and polymyalgia rheumatica in a Danish county: a prospective investigation, 1982–1985. Arthritis Rheum 1987 Mar; 30(3): 294–9

    Article  PubMed  CAS  Google Scholar 

  8. Noltorp S, Svensson B. High incidence of polymyalgia rheumatica and giant cell arteritis in a Swedish community. Clin Exp Rheumatol 1991 Jul–Aug; 9(4): 351–5

    PubMed  CAS  Google Scholar 

  9. Gran JT, Myklebust G. The incidence of polymyalgia rheumatica and temporal arteritis in the county of Aust Agder, south Norway: a prospective study 1987–94. J Rheumatol 1997 Sep; 24(9): 1739–43

    PubMed  CAS  Google Scholar 

  10. Gonzalez-Gay MA, Garcia-Porrua C, Rivas MJ, et al. Epidemiology of biopsy proven giant cell arteritis in northwestern Spain: trend over an 18 year period. Ann Rheum Dis 2001 Apr; 60(4): 367–71

    Article  PubMed  CAS  Google Scholar 

  11. Sonnenblick M, Nesher G, Friedlander Y, et al. Giant cell arteritis in Jerusalem: a 12-year epidemiological study. Br J Rheumatol 1994 Oct; 33(10): 938–41

    Article  PubMed  CAS  Google Scholar 

  12. Gonzalez-Gay MA, Miranda-Filloy JA, Lopez-Diaz MJ, et al. Giant cell arteritis in northwestern Spain: a 25-year epidemiologic study. Medicine (Baltimore) 2007 Mar; 86(2): 61–8

    Article  Google Scholar 

  13. Kobayashi S, Yano T, Matsumoto Y, et al. Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan: the first government-supported nationwide survey. Arthritis Rheum 2003 Aug 15; 49(4): 594–8

    Article  PubMed  Google Scholar 

  14. Crowson CS, Matteson EL, Myasoedova E, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum 2011 Mar; 63(3): 633–9

    Article  PubMed  Google Scholar 

  15. Salvarani C, Gabriel SE, O’Fallon WM, et al. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann Intern Med 1995 Aug 1; 123(3): 192–4

    PubMed  CAS  Google Scholar 

  16. Bas-Lando M, Breuer GS, Berkun Y, et al. The incidence of giant cell arteritis in Jerusalem over a 25-year period: annual and seasonal fluctuations. Clin Exp Rheumatol 2007 Jan–Feb; 25(1 Suppl. 44): S15–7

    PubMed  CAS  Google Scholar 

  17. Matteson EL, Gold KN, Bloch DA, et al. Long-term survival of patients with giant cell arteritis in the American College of Rheumatology giant cell arteritis classification criteria cohort. Am J Med 1996 Feb; 100(2): 193–6

    Article  PubMed  CAS  Google Scholar 

  18. Gonzalez-Gay MA, Blanco R, Abraira V, et al. Giant cell arteritis in Lugo, Spain, is associated with low longterm mortality. J Rheumatol 1997 Nov; 24(11): 2171–6

    PubMed  CAS  Google Scholar 

  19. Gran JT, Myklebust G, Wilsgaard T, et al. Survival in polymyalgia rheumatica and temporal arteritis: a study of 398 cases and matched population controls. Rheumatology (Oxford) 2001 Nov; 40(11): 1238–42

    Article  CAS  Google Scholar 

  20. Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, et al. Visual manifestations of giant cell arteritis: trends and clinical spectrum in 161 patients. Medicine (Baltimore) 2000 Sep; 79(5): 283–92

    Article  CAS  Google Scholar 

  21. Salvarani C, Cantini F, Boiardi L, et al. Polymyalgia rheumatica. Best Pract Res Clin Rheumatol 2004 Oct; 18(5): 705–22

    Article  PubMed  Google Scholar 

  22. Salvarani C, Gabriel SE, O’Fallon WM, et al. Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970–1991. Arthritis Rheum 1995 Mar; 38(3): 369–73

    Article  PubMed  CAS  Google Scholar 

  23. Gonzalez-Gay MA, Garcia-Porrua C, Vazquez-Caruncho M, et al. The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study. J Rheumatol 1999 Jun; 26(6): 1326–32

    PubMed  CAS  Google Scholar 

  24. Gonzalez-Gay MA. Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions. Semin Arthritis Rheum 2004 Apr; 33(5): 289–93

    Article  PubMed  Google Scholar 

  25. Gonzalez-Gay MA, Garcia-Porrua C, Vazquez-Caruncho M. Polymyalgia rheumatica in biopsy proven giant cell arteritis does not constitute a different subset but differs from isolated polymyalgia rheumatica. J Rheumatol 1998 Sep; 25(9): 1750–5

    PubMed  CAS  Google Scholar 

  26. Gonzalez-Gay MA, Amoli MM, Garcia-Porrua C, et al. Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. Semin Arthritis Rheum 2003 Aug; 33(1): 38–48

    Article  PubMed  CAS  Google Scholar 

  27. Dababneh A, Gonzalez-Gay MA, Garcia-Porrua C, et al. Giant cell arteritis and polymyalgia rheumatica can be differentiated by distinct patterns of HLA class II association. J Rheumatol 1998 Nov; 25(11): 2140–5

    PubMed  CAS  Google Scholar 

  28. Weyand CM, Hicok KC, Hunder GG, et al. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 1994 Oct 1; 121(7): 484–91

    PubMed  CAS  Google Scholar 

  29. Weyand CM, Tetzlaff N, Bjornsson J, et al. Disease patterns and tissue cytokine profiles in giant cell arteritis. Arthritis Rheum 1997 Jan; 40(1): 19–26

    Article  PubMed  CAS  Google Scholar 

  30. Weyand CM, Ma-Krupa W, Goronzy JJ. Immunopath-ways in giant cell arteritis and polymyalgia rheumatica. Autoimmun Rev 2004 Jan; 3(1): 46–53

    Article  PubMed  Google Scholar 

  31. Gonzalez-Gay MA, Hajeer AH, Dababneh A, et al. Inter-feron-gamma gene microsatellite polymorphisms in patients with biopsy-proven giant cell arteritis and isolated polymyalgia rheumatica. Clin Exp Rheumatol 2004; 22 (6 Suppl. 36): S18–20

    PubMed  CAS  Google Scholar 

  32. Gonzalez-Gay MA, Barros S, Lopez-Diaz MJ, et al. Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine (Baltimore) 2005 Sep; 84(5): 269–76

    Article  Google Scholar 

  33. Duhaut P, Pinede L, Bornet H, et al. Biopsy proven and biopsy negative temporal arteritis: differences in clinical spectrum at the onset of the disease. Groupe de Recherche sur l’Arterite a Cellules Geantes. Ann Rheum Dis 1999 Jun; 58(6): 335–41

    Article  PubMed  CAS  Google Scholar 

  34. Currey J. Scalp necrosis in giant cell arteritis and review of the literature. Br J Rheumatol 1997 Jul; 36(7): 814–6

    Article  PubMed  CAS  Google Scholar 

  35. Ward TN, Levin M. Headache in giant cell arteritis and other arteritides. Neurol Sci 2005 May; 26Suppl. 2: s134–7

    Article  PubMed  Google Scholar 

  36. Hutchinson J. Disease of the arteries: on a peculiar form of thrombotic arteritis of the aged which is sometimes productive of gangrene. Arch Surg 1890; 1: 323–9

    Google Scholar 

  37. Duhaut P, Berruyer M, Pinede L, et al. Anticardiolipin antibodies and giant cell arteritis: a prospective, multicenter case-control study. Groupe de Recherche sur l’Ar-terite a Cellules Geantes. Arthritis Rheum 1998 Apr; 41(4): 701–9

    Article  PubMed  CAS  Google Scholar 

  38. Huston KA, Hunder GG, Lie JT, et al. Temporal arteritis: a 25-year epidemiologic, clinical, and pathologic study. Ann Intern Med 1978 Feb; 88(2): 162–7

    PubMed  CAS  Google Scholar 

  39. Hunder GG. Clinical features of GCA/PMR. Clin Exp Rheumatol 2000 Jul–Aug; 18(4 Suppl. 20): S6–8

    PubMed  CAS  Google Scholar 

  40. Delecoeuillerie G, Joly P, Cohen de Lara A, et al. Poly-myalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticoster-oid regimens (11 year survey of 210 patients). Ann Rheum Dis 1988 Sep; 47(9): 733–9

    Article  PubMed  CAS  Google Scholar 

  41. Fledelius HC, Nissen KR. Giant cell arteritis and visual loss: a 3-year retrospective hospital investigation in a Danish county. Acta Ophthalmol (Copenh) 1992 Dec; 70(6): 801–5

    Article  CAS  Google Scholar 

  42. Liozon E, Herrmann F, Ly K, et al. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med 2001 Aug 15; 111(3): 211–7

    Article  PubMed  CAS  Google Scholar 

  43. Hayreh SS, Zimmerman B, Kardon RH. Visual improvement with corticosteroid therapy in giant cell arteritis: report of a large study and review of literature. Acta Ophthalmol Scand 2002 Aug; 80(4): 355–67

    Article  PubMed  Google Scholar 

  44. Nesher G, Nesher R, Rozenman Y, et al. Visual hallucinations in giant cell arteritis: association with visual loss. J Rheumatol 2001 Sep; 28(9): 2046–8

    PubMed  CAS  Google Scholar 

  45. Caselli RJ, Hunder GG. Neurologic complications of giant cell (temporal) arteritis. Semin Neurol 1994 Dec; 14(4): 349–53

    Article  PubMed  CAS  Google Scholar 

  46. Cid MC, Font C, Oristrell J, et al. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum 1998 Jan; 41(1): 26–32

    Article  PubMed  CAS  Google Scholar 

  47. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Gomez-Acebo I, et al. Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis. Medicine (Baltimore) 2009 Jul; 88(4): 227–35

    Article  Google Scholar 

  48. Salvarani C, Giannini C, Miller DV, et al. Giant cell arteritis: involvement of intracranial arteries. Arthritis Rheum 2006 Dec 15; 55(6): 985–9

    Article  PubMed  Google Scholar 

  49. Brodmann M, Dorr A, Hafner F, et al. Tongue necrosis as first symptom of giant cell arteritis (GCA). Clin Rheumatol 2009 Jun; 28Suppl. 1: S47–9

    Article  PubMed  Google Scholar 

  50. Mahevas M, Delastour V, Bussone G, et al. Scalp necrosis in giant cell arteritis. J Rheumatol 2007 Feb; 34(2): 442–3

    PubMed  Google Scholar 

  51. Liozon E, Ouattara B, Portal MF, et al. Head-and-neck swelling: an under-recognized feature of giant cell arteritis: a report of 37 patients. Clin Exp Rheumatol 2006 Mar–Apr; 24(2 Suppl. 41): S20–5

    PubMed  CAS  Google Scholar 

  52. Evans JM, O’Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis: a population-based study. Ann Intern Med 1995 Apr 1; 122(7): 502–7

    PubMed  CAS  Google Scholar 

  53. Gonzalez-Gay MA, Garcia-Porrua C, Pineiro A, et al. Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population-based study. Medicine (Baltimore) 2004 Nov; 83(6): 335–41

    Article  Google Scholar 

  54. Nuenninghoff DM, Hunder GG, Christianson TJ, et al. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum 2003 Dec; 48(12): 3522–31

    Article  PubMed  Google Scholar 

  55. Bongartz T, Matteson EL. Large-vessel involvement in giant cell arteritis. Curr Opin Rheumatol 2006 Jan; 18(1): 10–7

    Article  PubMed  Google Scholar 

  56. Kermani TA, Matteson EL, Hunder GG, et al. Symptomatic lower extremity vasculitis in giant cell arteritis: a case series. J Rheumatol 2009 Oct; 36(10): 2277–83

    Article  PubMed  Google Scholar 

  57. Scola CJ, Li C, Upchurch KS. Mesenteric involvement in giant cell arteritis: an underrecognized complication? Analysis of a case series with clinicoanatomic correlation. Medicine (Baltimore) 2008 Jan; 87(1): 45–51

    Article  Google Scholar 

  58. Calamia KT, Hunder GG. Giant cell arteritis (temporal arteritis) presenting as fever of undetermined origin. Arthritis Rheum 1981 Nov; 24(11): 1414–8

    Article  PubMed  CAS  Google Scholar 

  59. Zenone T. Fever of unknown origin in adults: evaluation of 144 cases in a non-university hospital. Scand J Infect Dis 2006; 38(8): 632–8

    Article  PubMed  Google Scholar 

  60. Salvarani C, Hunder GG. Musculoskeletal manifestations in a population-based cohort of patients with giant cell arteritis. Arthritis Rheum 1999 Jun; 42(6): 1259–66

    Article  PubMed  CAS  Google Scholar 

  61. Narvaez J, Nolla-Sole JM, Narvaez JA, et al. Musculoskeletal manifestations in polymyalgia rheumatica and temporal arteritis. Ann Rheum Dis 2001 Nov; 60(11): 1060–3

    Article  PubMed  CAS  Google Scholar 

  62. Gonzalez-Gay MA, Lopez-Diaz MJ, Barros S, et al. Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240 patients. Medicine (Baltimore) 2005 Sep; 84(5): 277–90

    Article  Google Scholar 

  63. Weyand CM, Fulbright JW, Hunder GG, et al. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 2000 May; 43(5): 1041–8

    Article  PubMed  CAS  Google Scholar 

  64. Liozon E, Jauberteau-Marchan MO, Ly K, et al. Giant cell arteritis with a low erythrocyte sedimentation rate: comments on the article by Salvarani and Hunder. Arthritis Rheum 2002 Dec 15; 47(6): 692–3; author reply 693–4

    Article  PubMed  Google Scholar 

  65. Lopez-Diaz MJ, Llorca J, Gonzalez-Juanatey C, et al. The erythrocyte sedimentation rate is associated with the development of visual complications in biopsy-proven giant cell arteritis. Semin Arthritis Rheum 2008 Oct; 38(2): 116–23

    Article  PubMed  Google Scholar 

  66. Parikh M, Miller NR, Lee AG, et al. Prevalence of a normal C-reactive protein with an elevated erythrocyte sedimentation rate in biopsy-proven giant cell arteritis. Ophthalmology 2006 Oct; 113(10): 1842–5

    Article  PubMed  Google Scholar 

  67. Hayreh SS, Podhajsky PA, Raman R, et al. Giant cell ar-teritis: validity and reliability of various diagnostic criteria. Am J Ophthalmol 1997 Mar; 123(3): 285–96

    PubMed  CAS  Google Scholar 

  68. Garcia-Martinez A, Hernandez-Rodriguez J, Espigol-Frigole G, et al. Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term followup of patients with giant cell arteritis. Arthritis Care Res (Hoboken) 2010 Jun; 62(6): 835–41

    Article  CAS  Google Scholar 

  69. Breuer GS, Nesher R, Nesher G. Effect of biopsy length on the rate of positive temporal artery biopsies. Clin Exp Rheumatol 2009 Jan–Feb; 27(1 Suppl. 52): S10–3

    PubMed  CAS  Google Scholar 

  70. Mahr A, Saba M, Kambouchner M, et al. Temporal artery biopsy for diagnosing giant cell arteritis: the longer, the better? Ann Rheum Dis 2006 Jun; 65(6): 826–8

    Article  PubMed  CAS  Google Scholar 

  71. Breuer GS, Nesher G, Nesher R. Rate of discordant findings in bilateral temporal artery biopsy to diagnose giant cell arteritis. J Rheumatol 2009 Apr; 36(4): 794–6

    Article  PubMed  Google Scholar 

  72. Brack A, Martinez-Taboada V, Stanson A, et al. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum 1999 Feb; 42(2): 311–7

    Article  PubMed  CAS  Google Scholar 

  73. Chatelain D, Duhaut P, Schmidt J, et al. Pathological features of temporal arteries in patients with giant cell arteritis presenting with permanent visual loss. Ann Rheum Dis 2009 Jan; 68(1): 84–8

    Article  PubMed  CAS  Google Scholar 

  74. Cox M, Gilks B. Healed or quiescent temporal arteritis versus senescent changes in temporal artery biopsy specimens. Pathology 2001 May; 33(2): 163–6

    Article  PubMed  CAS  Google Scholar 

  75. Miller DV, Isotalo PA, Weyand CM, et al. Surgical pathology of noninfectious ascending aortitis: a study of 45 cases with emphasis on an isolated variant. Am J Surg Pathol 2006 Sep; 30(9): 1150–8

    Article  PubMed  Google Scholar 

  76. Mari B, Monteagudo M, Bustamante E, et al. Analysis of temporal artery biopsies in an 18-year period at a community hospital. Eur J Intern Med 2009 Sep; 20(5): 533–6

    Article  PubMed  CAS  Google Scholar 

  77. Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, et al. Biopsy-negative giant cell arteritis: clinical spectrum and predictive factors for positive temporal artery biopsy. Semin Arthritis Rheum 2001 Feb; 30(4): 249–56

    Article  PubMed  CAS  Google Scholar 

  78. Rodriguez-Valverde V, Sarabia JM, Gonzalez-Gay MA, et al. Risk factors and predictive models of giant cell arteritis in polymyalgia rheumatica. Am J Med 1997 Apr; 102(4): 331–6

    Article  PubMed  CAS  Google Scholar 

  79. Achkar AA, Lie JT, Hunder GG, et al. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med 1994 Jun 15; 120(12): 987–92

    PubMed  CAS  Google Scholar 

  80. Narvaez J, Bernad B, Roig-Vilaseca D, et al. Influence of previous corticosteroid therapy on temporal artery biopsy yield in giant cell arteritis. Semin Arthritis Rheum 2007 Aug; 37(1): 13–9

    Article  PubMed  CAS  Google Scholar 

  81. Schmidt WA, Kraft HE, Vorpahl K, et al. Color duplex ultrasonography in the diagnosis of temporal arteritis. N Engl J Med 1997 Nov 6; 337(19): 1336–42

    Article  PubMed  CAS  Google Scholar 

  82. Arida A, Kyprianou M, Kanakis M, et al. The diagnostic value of ultrasonography-derived edema of the temporal artery wall in giant cell arteritis: a second meta-analysis. BMC Musculoskelet Disord 2010; 11: 44

    Article  PubMed  Google Scholar 

  83. Maldini C, Depinay-Dhellemmes C, Tra TT, et al. Limited value of temporal artery ultrasonography examinations for diagnosis of giant cell arteritis: analysis of 77 subjects. J Rheumatol 2010 Nov; 37(11): 2326–30

    Article  PubMed  Google Scholar 

  84. Schmidt WA, Seifert A, Gromnica-Ihle E, et al. Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis. Rheumatology (Oxford) 2008 Jan; 47(1): 96–101

    Article  CAS  Google Scholar 

  85. Geiger J, Bley T, Uhl M, et al. Diagnostic value of T2-weighted imaging for the detection of superficial cranial artery inflammation in giant cell arteritis. J Magn Reson Imaging 2010 Feb; 31(2): 470–4

    Article  PubMed  Google Scholar 

  86. Agard C, Barrier JH, Dupas B, et al. Aortic involvement in recent-onset giant cell (temporal) arteritis: a case-control prospective study using helical aortic computed tomo-densitometric scan. Arthritis Rheum 2008 May 15; 59(5): 670–6

    Article  PubMed  Google Scholar 

  87. Marie I, Proux A, Duhaut P, et al. Long-term follow-up of aortic involvement in giant cell arteritis: a series of 48 patients. Medicine (Baltimore) 2009 May; 88(3): 182–92

    Article  Google Scholar 

  88. Hautzel H, Sander O, Heinzel A, et al. Assessment of large-vessel involvement in giant cell arteritis with 18F-FDG PET: introducing an ROC-analysis-based cutoff ratio. J Nucl Med 2008 Jul; 49(7): 1107–13

    Article  PubMed  Google Scholar 

  89. Lehmann P, Buchtala S, Achajew N, et al. 18F-FDG PET as a diagnostic procedure in large vessel vasculitis: a controlled, blinded re-examination ofroutine PET scans. Clin Rheumatol 2011 Jan; 30(1): 37–42

    Article  PubMed  Google Scholar 

  90. Hayashida T, Sueyoshi E, Sakamoto I, et al. PET features of aortic diseases. Am J Roentgenol 2010 Jul; 195(1): 229–33

    Article  Google Scholar 

  91. Both M, Ahmadi-Simab K, Reuter M, et al. MRI and FDG-PET in the assessment of inflammatory aortic arch syndrome in complicated courses of giant cell arteritis. Ann Rheum Dis 2008 Jul; 67(7): 1030–3

    Article  PubMed  CAS  Google Scholar 

  92. Chuang TY, Hunder GG, Ilstrup DM, et al. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med 1982 Nov; 97(5): 672–80

    PubMed  CAS  Google Scholar 

  93. Salvarani C, Gabriel S, Hunder GG. Distal extremity swelling with pitting edema in polymyalgia rheumatica: report on nineteen cases. Arthritis Rheum 1996 Jan; 39(1): 73–80

    Article  PubMed  CAS  Google Scholar 

  94. Ceccato F, Roverano SG, Papasidero S, et al. Peripheral musculoskeletal manifestations in polymyalgia rheumatica. J Clin Rheumatol 2006 Aug; 12(4): 167–71

    Article  PubMed  Google Scholar 

  95. Salvarani C, Macchioni PL, Tartoni PL, et al. Polymyalgia rheumatica and giant cell arteritis: a 5-year epidemiologic and clinical study in Reggio Emilia, Italy. Clin Exp Rheumatol 1987 Jul–Sep; 5(3): 205–15

    PubMed  CAS  Google Scholar 

  96. Healey LA. Long-term follow-up of polymyalgia rheumatica: evidence for synovitis. Semin Arthritis Rheum 1984 May; 13(4): 322–8

    Article  PubMed  CAS  Google Scholar 

  97. Gonzalez-Gay MA, Rodriguez-Valverde V, Blanco R, et al. Polymyalgia rheumatica without significantly increased erythrocyte sedimentation rate: a more benign syndrome. Arch Intern Med 1997 Feb 10; 157(3): 317–20

    Article  PubMed  CAS  Google Scholar 

  98. Cantini F, Salvarani C, Olivieri I, et al. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthritis Rheum 2000 Aug; 30(1): 17–24

    Article  PubMed  CAS  Google Scholar 

  99. Gonzalez-Gay MA, Agudo M, Martinez-Dubois C, et al. Medical management of polymyalgia rheumatica. Expert Opin Pharmacother 2010 May; 11(7): 1077–87

    Article  PubMed  CAS  Google Scholar 

  100. Cantini F, Niccoli L, Salvarani C, et al. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 2001 Dec; 44(12): 2933–5

    Article  PubMed  CAS  Google Scholar 

  101. Cantini F, Niccoli L, Nannini C, et al. Inflammatory changes of hip synovial structures in polymyalgia rheu-matica. Clin Exp Rheumatol 2005 Jul–Aug; 23(4): 462–8

    PubMed  CAS  Google Scholar 

  102. Cantini F, Salvarani C, Olivieri I, et al. Inflamed shoulder structures in polymyalgia rheumatica with normal erythrocyte sedimentation rate. Arthritis Rheum 2001 May; 44(5): 1155–9

    Article  PubMed  CAS  Google Scholar 

  103. Jimenez-Palop M, Naredo E, Humbrado L, et al. Ultrasonographic monitoring of response to therapy in poly-myalgia rheumatica. Ann Rheum Dis 2010 May; 69(5): 879–82

    Article  PubMed  CAS  Google Scholar 

  104. Macchioni P, Catanoso MG, Pipitone N, et al. Longitudinal examination with shoulder ultrasound ofpatients with polymyalgia rheumatica. Rheumatology (Oxford) 2009 Dec; 48(12): 1566–9

    Article  Google Scholar 

  105. Mori S, Koga Y, Ito K. Clinical characteristics of poly-myalgia rheumatica in Japanese patients: evidence of synovitis and extracapsular inflammatory changes by fat suppression magnetic resonance imaging. Mod Rheumatol 2007; 17(5): 369–75

    Article  PubMed  Google Scholar 

  106. Marzo-Ortega H, Rhodes LA, Tan AL, et al. Evidence for a different anatomic basis for joint disease localization in polymyalgia rheumatica in comparison with rheumatoid arthritis. Arthritis Rheum 2007 Oct; 56(10): 3496–501

    Article  PubMed  Google Scholar 

  107. McGonagle D, Pease C, Marzo-Ortega H, et al. Comparison of extracapsular changes by magnetic resonance imaging in patients with rheumatoid arthritis and polymyalgia rheumatica. J Rheumatol 2001 Aug; 28(8): 1837–41

    PubMed  CAS  Google Scholar 

  108. Salvarani C, Barozzi L, Cantini F, et al. Cervical inter-spinous bursitis in active polymyalgia rheumatica. Ann Rheum Dis 2008 Jun; 67(6): 758–61

    Article  PubMed  CAS  Google Scholar 

  109. Blockmans D, De Ceuninck L, Vanderschueren S, et al. Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients. Rheumatology (Oxford) 2007 Apr; 46(4): 672–7

    Article  CAS  Google Scholar 

  110. Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990 Aug; 33(8): 1122–8

    Article  PubMed  CAS  Google Scholar 

  111. Bird HA, Esselinckx W, Dixon AS, et al. An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis 1979 Oct; 38(5): 434–9

    Article  PubMed  CAS  Google Scholar 

  112. Dasgupta B, Salvarani C, Schirmer M, et al. Developing classification criteria for polymyalgia rheumatica: comparison of views from an expert panel and wider survey. J Rheumatol 2008 Feb; 35(2): 270–7

    PubMed  Google Scholar 

  113. Gonzalez-Gay MA, Garcia-Porrua C, Salvarani C, et al. The spectrum of conditions mimicking polymyalgia rheumatica in Northwestern Spain. J Rheumatol 2000 Sep; 27(9): 2179–84

    PubMed  CAS  Google Scholar 

  114. Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Takayasu arteritis and giant cell arteritis: a spectrum within the same disease? Medicine (Baltimore) 2009 Jul; 88(4): 221–6

    Article  Google Scholar 

  115. Smetana GW, Shmerling RH. Does this patient have temporal arteritis? JAMA 2002 Jan 2; 287(1): 92–101

    Article  PubMed  Google Scholar 

  116. Proven A, Gabriel SE, Orces C, et al. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003 Oct 15; 49(5): 703–8

    Article  PubMed  CAS  Google Scholar 

  117. Hunder GG, Sheps SG, Allen GL, et al. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. Ann Intern Med 1975 May; 82(5): 613–8

    PubMed  CAS  Google Scholar 

  118. Mazlumzadeh M, Hunder GG, Easley KA, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum 2006 Oct; 54(10): 3310–8

    Article  PubMed  CAS  Google Scholar 

  119. Chevalet P, Barrier JH, Pottier P, et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol 2000 Jun; 27(6): 1484–91

    PubMed  CAS  Google Scholar 

  120. Gonzalez-Gay MA, Blanco R, Rodriguez-Valverde V, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum 1998 Aug; 41(8): 1497–504

    Article  PubMed  CAS  Google Scholar 

  121. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009 Mar; 68(3): 318–23

    Article  PubMed  CAS  Google Scholar 

  122. Hoffman GS, Cid MC, Hellmann DB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002 May; 46(5): 1309–18

    Article  PubMed  CAS  Google Scholar 

  123. Jover JA, Hernandez-Garcia C, Morado IC, et al. Combined treatment of giant-cell arteritis with methotrexate and prednisone: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001 Jan 16; 134(2): 106–14

    PubMed  CAS  Google Scholar 

  124. Spiera RF, Mitnick HJ, Kupersmith M, et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment ofgiant cell arteritis (GCA). Clin Exp Rheumatol 2001 Sep–Oct; 19(5): 495–501

    PubMed  CAS  Google Scholar 

  125. Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 2007 Aug; 56(8): 2789–97

    Article  PubMed  CAS  Google Scholar 

  126. Andonopoulos AP, Meimaris N, Daoussis D, et al. Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis [letter]. Ann Rheum Dis 2003 Nov; 62(11): 1116

    Article  PubMed  CAS  Google Scholar 

  127. Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007 May 1; 146(9): 621–30

    PubMed  Google Scholar 

  128. Hayreh SS, Zimmerman B. Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology 2003 Jun; 110(6): 1204–15

    Article  PubMed  Google Scholar 

  129. Duhaut P, Pinede L, Demolombe-Rague S, et al. Giant cell arteritis and cardiovascular risk factors: a multicenter, prospective case-control study. Groupe de Recherche sur l’Arterite a Cellules Geantes. Arthritis Rheum 1998 Nov; 41(11): 1960–5

    Article  PubMed  CAS  Google Scholar 

  130. Le Page L, Duhaut P, Seydoux D, et al. Incidence of cardiovascular events in giant cell arteritis: preliminary results of a prospective double cohort study (GRACG) [in French]. Rev Med Interne 2006 Feb; 27(2): 98–105

    Article  PubMed  Google Scholar 

  131. Lee MS, Smith SD, Galor A, et al. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum 2006 Oct; 54(10): 3306–9

    Article  PubMed  Google Scholar 

  132. Nesher G, Berkun Y, Mates M, et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004 Apr; 50(4): 1332–7

    Article  PubMed  CAS  Google Scholar 

  133. Gonzalez-Gay MA, Pineiro A, Gomez-Gigirey A, et al. Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine (Baltimore) 2004 Nov; 83(6): 342–7

    Article  Google Scholar 

  134. Narvaez J, Bernad B, Gomez-Vaquero C, et al. Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis. Clin Exp Rheumatol 2008 May–Jun; 26(3 Suppl. 49): S57–62

    PubMed  CAS  Google Scholar 

  135. Salvarani C, Della Bella C, Cimino L, et al. Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. Rheumatology (Oxford) 2009 Mar; 48(3): 250–3

    Article  CAS  Google Scholar 

  136. Berger CT, Wolbers M, Meyer P, et al. High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition. Rheumatology (Oxford) 2009 Mar; 48(3): 258–61

    Article  CAS  Google Scholar 

  137. Weyand CM, Kaiser M, Yang H, et al. Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthritis Rheum 2002 Feb; 46(2): 457–66

    Article  PubMed  CAS  Google Scholar 

  138. Schmidt WA, Moll A, Seifert A, et al. Prognosis of large-vessel giant cell arteritis. Rheumatology (Oxford) 2008 Sep; 47(9): 1406–8

    Article  CAS  Google Scholar 

  139. Pipitone N, Salvarani C. Improving therapeutic options for patients with giant cell arteritis. Curr Opin Rheumatol 2008 Jan; 20(1): 17–22

    Article  PubMed  CAS  Google Scholar 

  140. Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007 Dec; 66(12): 1560–7

    Article  PubMed  CAS  Google Scholar 

  141. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010 Nov; 62(11): 1515–26

    Article  Google Scholar 

  142. Moosig F, Holle JU, Gross WL. Value of anti-infective chemoprophylaxis in primary systemic vasculitis: what is the evidence? Arthritis Res Ther 2009; 11(5): 253

    Article  PubMed  CAS  Google Scholar 

  143. Kyle V, Hazleman BL. Treatment of polymyalgia rheumatica and giant cell arteritis: I. steroid regimens in the first two months. Ann Rheum Dis 1989 Aug; 48(8): 658–61

    Article  PubMed  CAS  Google Scholar 

  144. Salvarani C, Cantini F, Niccoli L, et al. Acute-phase re-actants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum 2005 Feb 15; 53(1): 33–8

    Article  PubMed  Google Scholar 

  145. Kremers HM, Reinalda MS, Crowson CS, et al. Relapse in a population based cohort of patients with polymyalgia rheumatica. J Rheumatol 2005 Jan; 32(1): 65–73

    PubMed  Google Scholar 

  146. Dasgupta B, Dolan AL, Panayi GS, et al. An initially double-blind controlled 96 week trial of depot methyl-prednisolone against oral prednisolone in the treatment of polymyalgia rheumatica. Br J Rheumatol 1998 Feb; 37(2): 189–95

    Article  PubMed  CAS  Google Scholar 

  147. Salvarani C, Cantini F, Olivieri I, et al. Corticosteroid injections in polymyalgia rheumatica: a double-blind, prospective, randomized, placebo controlled study. J Rheumatol 2000 Jun; 27(6): 1470–6

    PubMed  CAS  Google Scholar 

  148. van der Veen MJ, Dinant HJ, van Booma-Frankfort C, et al. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis 1996 Apr; 55(4): 218–23

    Article  PubMed  Google Scholar 

  149. Caporali R, Cimmino MA, Ferraccioli G, et al. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2004 Oct 5; 141(7): 493–500

    PubMed  CAS  Google Scholar 

  150. Cimmino MA, Salvarani C, Macchioni P, et al. Long-term follow-up of polymyalgia rheumatica patients treated with methotrexate and steroids. Clin Exp Rheumatol 2008 May–Jun; 26(3): 395–400

    PubMed  CAS  Google Scholar 

  151. Salvarani C, Macchioni P, Manzini C, et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment ofpolymyalgia rheumatica: a randomized trial. Ann Intern Med 2007 May 1; 146(9): 631–9

    PubMed  Google Scholar 

  152. Kermani TA, Schafer VS, Crowson CS, et al. Increase in age at onset of giant cell arteritis: a population-based study. Ann Rheum Dis 2010 Apr; 69(4): 780–1

    Article  PubMed  Google Scholar 

  153. Loya AM, Gonzalez-Stuart A, Rivera JO. Prevalence of polypharmacy, polyherbacy, nutritional supplement use and potential product interactions among older adults living on the United States-Mexico border: a descriptive, questionnaire-based study. Drugs Aging 2009; 26(5): 423–36

    Article  PubMed  Google Scholar 

  154. Chevalet P, Barrier JH, Glemarec J, et al. Horton’s disease in elderly patients aged over 75: clinical course, complications of corticotherapy. Comparative study of 164 patients. Towards a reduced initial dose [in French]. Rev Med Interne 2001 Jul; 22(7): 624–30

    Article  PubMed  CAS  Google Scholar 

  155. Nesher G, Sonnenblick M, Friedlander Y. Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients. J Rheumatol 1994 Jul; 21(7): 1283–6

    PubMed  CAS  Google Scholar 

  156. Langford CA. Vasculitis in the geriatric population. Rheum Dis Clin North Am 2007 Feb; 33(1): 177–95

    Article  PubMed  Google Scholar 

  157. Orr R. Contribution of muscle weakness to postural instability in the elderly: a systematic review. Eur J Phys Rehabil Med 2010 Jun; 46(2): 183–220

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Department of Internal Medicine and RECIF, Amiens University Hospital, Amiens, France

    Jean Schmidt

  2. Division of Rheumatology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA

    Jean Schmidt &  Kenneth J. Warrington

Authors
  1. Jean Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenneth J. Warrington
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenneth J. Warrington.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schmidt, J., Warrington, K.J. Polymyalgia Rheumatica and Giant Cell Arteritis in Older Patients. Drugs Aging 28, 651–666 (2011). https://doi.org/10.2165/11592500-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11592500-000000000-00000

Keywords

Search

Navigation